Lead Investigator Name Institution Email Collaborator(s) Collaborator Institutions Therapeutic Area Cardiometabolic CNS Disorders Immunology and Inflammation Oncology Other If you indicated 'Other' for Therapeutic Area, please describe further Have you previously received a commercialization grant or other commercialization funding for this project? Yes No If yes, please indicate the grant and amount of funding: Please fill out the questions below to describe your therapeutic-focused project. Note that your responses are not meant to be exhaustive or definitive. The goal is to provide TIAP with an overview of the project background, stage, tools available, etc. If there is a fit, the TIAP team will engage with you to gain a fuller understanding of the approach and work with you to refine any proposed drug development activities prior to proceeding to the next stage. (250 words or less for each question). 1. Please briefly describe your therapeutic target of interest and your rationale for pursuing it. How did you identify the target or your novel targeting approach? What is known about the target’s mechanism of action? 2. Which therapeutic indication(s) are you focused on? Please provide an overview of evidence supporting the connection between the target and the indication. This can include multi-omic data, including genomic/genetic association studies, and targeted perturbations, such as knock-down/knock-out studies, overexpression studies, or modulation with a tool compound or broad modulator. 3. How does your proposed approach address an unmet medical need? 4. Please comment on the expected safety profile associated with the target. What is the target protein’s expression profile (in normal and disease states)? How conserved is the target with its closest protein homologues? Are there adverse effects to perturbing the target and are they addressable? 5. What are the available tools/assays/models for drug development (e.g., primary drug screening assay (biochemical or cell-based), biological activity assays, binding assays, tool compounds, organoid or animal disease models)? Indicate which are proprietary to you or your collaborators. 6. Describe any drug discovery activities that have taken place to date or IP filed (optional). List 3 key publications describing the state-of-the-art. Send
